For many years, pathogenetic concepts and the results of clinical trials supported the view that anti-IgE treatment is specifically effective in allergic asthma. However, there is now growing clinical and mechanistic evidence suggesting that treatment with the anti-IgE antibody omalizumab can be effective in patients with intrinsic asthma. Therefore, large and well-controlled clinical trials with anti-IgE are urgently warranted in patients with intrinsic asthma.

In addition, there is a need to find new biomarkers which can identify patients with asthma who respond to anti-IgE treatment.

Authors : Lommatzsch, M., Korn, S., Buhl, R., Virchow, J. C.
Read Full Article